To the full analysis
Fresenius Medical Care AG & Co. KGaA stock: growth
FME.DEFresenius Medical Care AG & Co. KGaA reported $21.75B in revenue for fiscal 2025, up 1.5% on the prior year, up 1.9% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
6%
per year from 2006 to 2025, per share 6.1%
Earnings (Annual rate)
4.7%
per year from 2006 to 2025, per share 4.8%
Free cash flow (Annual rate)
9.2%
per year from 2006 to 2025, per share 9.2%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 1.9% | 2.5% | 6.0% |
| Revenue per share | 2.1% | 3.0% | 6.1% |
| Earnings | −3.4% | 0.4% | 4.7% |
| Earnings per share | −3.2% | 0.8% | 4.8% |
| Free cash flow | −3.8% | 38.9% | 9.2% |
| Free cash flow per share | −3.6% | 39.6% | 9.2% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $7.14B | $450.65M | $369.96M |
| 2007 | $7.39B | $545.03M | $471.16M |
| 2008 | $8.45B | $650.81M | $261.91M |
| 2009 | $8.7B | $689.21M | $591.66M |
| 2010 | $10.04B | $815.28M | $703.62M |
| 2011 | $10.94B | $915.79M | −$801.09M |
| 2012 | $11.56B | $994.4M | $1.14B |
| 2013 | $11.72B | $890.65M | $1.03B |
| 2014 | $14.43B | $952.26M | $8.2M |
| 2015 | $16.96B | $1.04B | $72.97M |
| 2016 | $18.87B | $1.31B | $103.26M |
| 2017 | $19.71B | $1.42B | $451M |
| 2018 | $18.34B | $2.2B | $2.22M |
| 2019 | $19.37B | $1.33B | $364.56M |
| 2020 | $19.79B | $1.29B | $2.38B |
| 2021 | $19.52B | $1.07B | $1.81B |
| 2022 | $21.49B | $746.2M | $1.6B |
| 2023 | $21.56B | $552.94M | $2.15B |
| 2024 | $21.43B | $596.06M | $1.87B |
| 2025 | $21.75B | $1.08B | $1.96B |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 29 Feb 2024)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.